Equecabtagene autoleucel showed high efficacy in relapsed/refractory multiple myeloma, with a 96% overall response rate and 42.6% complete response rate at three months. Minimal residual disease ...
VIENNA, Va., November 07, 2024--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025. VIENNA ...
Tottenham Hotspur defender Radu Dragusin reportedly makes a decision over a possible exit from the North London giants in January amid his lack of game time. Tottenham Hotspur defender Radu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback